Brokerage firm Prabhudas Lilladher has started coverage on Global Health, the company behind the Medanta brand, with a 'Buy' rating and a price target of Rs 1,750 per share. Analysts expect operating profits to grow strongly as newer hospitals in Lucknow and Noida stabilize. While the company is spending heavily on expansion, this move aims to increase its hospital network significantly over the next few years.
Brokerage firm Prabhudas Lilladher has issued a 'Buy' rating on Global Health, the hospital operator known for its Medanta brand, setting a target price of Rs 1,750 per share. The positive outlook is primarily based on expectations of a jump in operating earnings as some of the company's newer facilities move past their initial start-up phase and begin contributing more effectively to the bottom line.
Global Health has been in an aggressive growth phase, which has impacted its profit margins recently. In the fiscal year 2026, the company reported total income of Rs 45,089 million, marking a solid 19.6% increase compared to the previous year. Net profit also rose by 15.1% to Rs 5,541 million. However, its operating margin—a key measure of core business profitability—dipped to 23.4% during the same period. This decline was largely attributed to the high costs associated with launching and stabilizing new hospital units, particularly the facility in Noida.
Analysts at Prabhudas Lilladher believe that the period of heavy spending on these new units is shifting toward a phase of higher efficiency. The company currently manages 3,737 beds across several cities, including Gurugram, Indore, Ranchi, Lucknow, Patna, and Noida. The expansion plan is ambitious, with management targeting the addition of approximately 3,368 new beds over the next three to four years. As the Lucknow and Noida units mature, the brokerage expects the company to see faster growth in operating profits.
While the long-term outlook appears positive to the brokerage, the company faces distinct risks that investors may want to track. The primary challenge remains the execution of such a large-scale expansion. Building and filling thousands of new hospital beds requires significant capital and operational focus. If the new hospitals take longer than expected to become profitable or if patient demand does not rise as quickly as planned, the company's margins could remain under pressure. Additionally, the healthcare sector is highly competitive, and any regulatory changes regarding medical service pricing could impact future earnings.
As of the latest reports, the company maintains a net cash position of Rs 5,906 million, which provides some financial flexibility as it continues its expansion. The key for investors going forward will be monitoring how quickly the Noida and Lucknow facilities can improve their performance and whether the company can successfully manage the operational costs of its growing network without stretching its finances too thin.